Tirzepatide Lyophilized Powder is a pharmaceutical formulation prepared using freeze-drying technology,with the active ingredient being Tirzepatide. Lyophilization technology removes moisture through low-temperature sublimation,transforming drugs into loose and porous solid powders.This process can significantly improve the stability of drugs,extend shelf life,and reduce degradation risks during transportation and storage.As an innovative drug, Tirzepatide's core characteristic lies in its dual agonist mechanism of action. It targets both glucose dependent insulinotropic polypeptide (GIP) receptors and glucagon like peptide-1(GLP-1)receptors,achieving dual goals of blood glucose control and weight management by simulating the physiological effects of these two gut hormones. GIP and GLP-1 are both secreted by the intestine. The former mainly promotes insulin secretion and inhibits gastric acid secretion, while the latter regulates blood sugar by delaying gastric emptying, suppressing appetite, and promoting insulin secretion.Tirzepatide integrates two insulin promoting effects into a single molecule,forming a new drug category for the treatment of type 2 diabetes.
We not only provide pure powder and capsules, but also other dosage forms. If necessary, please contact our sales team.
Our products
Tirzepatide COA
Tirzepatide Lyophilized Powder is a core raw material form of GIP/GLP -1 receptor dual agonist. The freeze-drying process keeps it stable in storage and transportation. Its core uses focus on the treatment of type 2 diabetes, obesity and related metabolic disease management,clinical and basic medical research,as well as drug preparation development and production. It also shows potential application value in cardiovascular,neurometabolic and other fields.
Core basic characteristics and value of freeze-dried dosage forms
Essence of Matter and Mechanism of Action
Tirzepatide is an artificially synthesized peptide compound that acts as a dual agonist of GIP (glucose dependent insulinotropic polypeptide) and GLP-1 (glucagon like peptide-1) receptors, with a dual synergistic mechanism of action
GLP-1 receptor activation: promotes glucose dependent insulin secretion, inhibits glucagon release, delays gastric emptying to reduce postprandial blood glucose fluctuations, and acts on the central nervous system to suppress appetite and reduce calorie intake.
GIP receptor activation: enhances insulin sensitivity, improves beta cell function, and synergizes with GLP-1 receptors to further improve blood glucose control. It also plays an auxiliary role in weight regulation, promoting the conversion of white fat to brown fat and increasing energy expenditure efficiency.
The unique advantages of freeze-dried powder
Freeze drying is a process of removing water from liquid Tirzepatide by sublimation in a vacuum environment after freezing. The core value of this formulation is reflected in the following aspects:
| Feature | Specific advantages | Application scenario value |
| Stability improvement | Can be stored for a long time (usually 2-3 years)at 2-8 ℃ to avoid the decrease in activity of peptides caused by hydrolysis and oxidation | Facilitating large-scale production,transportation,and clinical storage of pharmaceutical raw materials |
| Purity maintenance | The freeze-drying process removes moisture and some impurities, and the purity of the finished product can reach over 99% | Ensure the consistency of drug efficacy of the formulation and reduce the risk of adverse reactions |
| Convenience of reconstitution | It can be quickly dissolved with injection water or antibacterial water to form a clear solution for subcutaneous injection | Adapting to the rapid clinical drug delivery needs and facilitating flexible dosage configuration in scientific research |
| Accurate and controllable dosage | Packaged in fixed specifications (such as 10mg, 30mg, 50mg/bottle), the dosage can be accurately adjusted after reconstitution | Meet the individualized treatment needs of different patients (such as diabetes and obesity) |
Core clinical therapeutic purposes
Tirzepatide Lyophilized Powder is the core raw material for the preparation of diabetes drugs such as Mounjaro, which has irreplaceable value in the treatment of type 2 diabetes. It can be used for the comprehensive control of blood glucose and can reduce glycosylated hemoglobin (HbA1c). Clinical data shows that when combined with basal insulin or metformin, Tirzepatide can reduce patients' HbA1c by 1.5% -2.0%, which is superior to some single target GLP-1 receptor agonists. Its dual activation mechanism can simultaneously control fasting blood glucose and postprandial blood glucose, reduce blood glucose fluctuations, and reduce the risk of complications of diabetes. It can also reduce the risk of hypoglycemia. It is glucose dependent. It can only promote insulin secretion when blood sugar rises, avoiding the common hypoglycemic adverse reactions in traditional insulin treatment. It is especially suitable for the elderly or type 2 diabetes patients with liver and kidney dysfunction.
It is also used for the protection and repair of beta cell function. Long term use can improve the secretion function of pancreatic beta cells and delay the rate of beta cell decline. Research has shown that Tirzepatide can activate GIP receptors, promote β - cell proliferation, reduce apoptosis, provide additional therapeutic benefits for patients with longer disease duration and impaired β - cell function, and delay disease progression. In addition to blood glucose, it can also reduce the levels of low-density lipoprotein cholesterol (LDL - C) and triglycerides in patients, improve blood lipid profile, reduce insulin resistance, and have a synergistic effect on the symptoms of metabolic syndrome often associated with type 2 diabetes. After reconstitution of freeze-dried powder, it can be prepared into subcutaneous injections once a week. Compared with daily hypoglycemic drugs, it significantly improves patient medication compliance, especially suitable for busy work and elderly people who are prone to missed medication. The commonly used starting dose in clinical practice is 2.5mg/week, gradually titrated to 5mg, 10mg, or 15mg/week according to blood glucose control.
Zepbound, which uses Tirzepatide freeze-dried powder as raw material, is a drug approved by FDA for obesity treatment. It is a targeted weight loss for severe obesity, and is applicable to adult patients with BMI ≥ 30kg/m ², or BMI ≥ 27kg/m ² and obesity related complications such as hypertension, hyperlipidemia, and type 2 diabetes. Clinical studies have shown that high-dose (15mg/week) Tirzepatide treatment for 72 weeks resulted in an average weight loss of 15% -20% in patients, significantly better than traditional weight loss drugs and single target GLP-1 receptor agonists. The dual regulation of appetite and metabolism reduces calorie intake through central appetite suppression, while delaying gastric emptying and prolonging satiety. It can also regulate fat metabolism, promote fat breakdown and reduce fat synthesis, achieving a healthy weight loss effect of "reducing fat without losing muscle" and improving body composition.
The auxiliary improvement of obesity related complications is obstructive sleep apnea (OSA) associated with obesity, which can be reduced by weight loss to alleviate airway compression and improve the frequency of apnea; For obesity related joint pain, weight loss can reduce joint load and alleviate pain symptoms; At the same time, it can also reduce the risk factors of cardiovascular disease in obese patients. Its long-term weight maintenance is a formulation prepared from freeze-dried powder that can be used as a maintenance medication for long-term weight management. After the patient reaches the target weight, low-dose maintenance treatment is administered to avoid weight rebound and provide a solution for chronic management of obesity.
Pre clinical studies and preliminary clinical trials have shown that Tirzepatide can alleviate non-alcoholic fatty liver disease (NASH) by improving insulin resistance, reducing liver fat deposition, and inhibiting liver inflammation. Freeze dried powder provides stable raw material support for clinical research on this type of expanded indication, and is expected to become a new choice for the treatment of NASH. Polycystic ovary syndrome is often accompanied by symptoms such as insulin resistance, obesity, and hyperandrogenism. Tirzepatide can improve insulin resistance, regulate hormone levels, reduce weight, assist in improving patients' menstrual cycle and ovulation function. The stable properties of freeze-dried powder make it easy to conduct relevant clinical trials and explore personalized treatments. Obstructive sleep apnea (OSA) is a serious obesity related complication, and its core cause is the accumulation of neck fat leading to airway stenosis. Tirzepatide reduces neck fat, broadens airways, and lowers the apnea hypopnea index (AHI) through weight loss. The formulation prepared from freeze-dried powder can be used as an adjuvant therapy for OSA, especially for patients who cannot tolerate ventilator treatment.
Clinical and Basic Medical Research Applications
Tirzepatide Lyophilized Powder is a core tool in the field of metabolic disease research due to its high purity and good stability. Its research applications cover multiple dimensions:
Research on Metabolic Mechanisms
Exploration of receptor signaling pathways
Used to study the downstream signaling pathways after synergistic activation of GIP and GLP-1 receptors, such as the regulatory mechanisms of PI3K/Akt, MAPK and other pathways on blood glucose and fat metabolism, providing theoretical basis for the development of multi-target metabolic drugs.
Research on regulation of fat metabolism
Through animal models (such as obese mice and diabetes rats), observe the effects of Tirzepatide on white fat browning, adipocyte differentiation and lipolysis, and identify its role targets in energy metabolism.
Research on the protective mechanism of pancreatic islet function
In vitro pancreatic islet cell culture or in vivo animal experiments, investigate the effects of Tirzepatide on β - cell proliferation, apoptosis, and insulin secretion function, and explore its molecular mechanism of delaying pancreatic islet function decline.
Drug comparison and optimization research
Study on the differences in therapeutic efficacy of similar drugs
Used to compare with single or triple target agonists such as Semaglutide and Retatrutide, evaluate the differences in blood glucose control, weight loss effect, safety, etc., and provide data support for clinical drug selection.
Optimization of dosage form and administration method
Based on freeze-dried powder, explore the development of new dosage forms such as microsphere formulations and oral formulations, study the pharmacokinetic parameters (such as half-life and bioavailability) under different administration methods, and provide technical directions for improving patient compliance.
Exploration of combined medication scheme
Study the synergistic effect of Tirzepatide combined with metformin, SGLT -2 inhibitor, insulin and other drugs, optimize the combined treatment scheme for type 2 diabetes and obesity, and reduce the dose and adverse reaction risk of single drug.
Preclinical exploration of expanding indications
Cardiovascular disease
To study the improvement of hypertension and atherosclerosis, observe the effect of Tirzepatide on vascular endothelial function and inflammatory factor level through animal models, and evaluate its potential in the prevention of cardiovascular complications.
Neurodegenerative diseases
Preclinical studies have shown that Tirzepatide can improve high glucose induced neurodegeneration, overcome neuronal insulin resistance, and is expected to be used in research on metabolic related neurological diseases such as Alzheimer's disease and Parkinson's disease.
Kidney disease
Explore its protective effect on diabetes nephropathy, study its impact on glomerular filtration rate and urinary protein level, and provide a new research direction for the treatment of diabetes nephropathy.
Hot Tags: tirzepatide lyophilized powder, China tirzepatide lyophilized powder manufacturers, suppliers, AOD 9604 Capsules, AOD 9604 Spray, bodybuilding peptide, Semaglutide Peptide 10mg, SLU PP 332 Injection, Tirzepatide Lyophilized Powder
